Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Preliminary Bioequivalence Study of UHAC 62 XX Tablets Compared With a Capsule Formulation in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: UHAC 62 XX - TF1 tablet
Drug: UHAC 62 XX - TF2 tablet
Drug: UHAC 62 XX - capsules

First Posted Date: 2014-07-02

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9

Registration Number: NCT02180477

Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac
Drug: Meloxicam

First Posted Date: 2014-07-02

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9984

Registration Number: NCT02180516

Bioequivalence Study of UHAC 62 XX Tablets Compared With Capsules in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: UHAC 62 XX tablet
Drug: UHAC 62 XX capsule

First Posted Date: 2014-07-02

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT02180490

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1356 BS PIB - low dose
Drug: BI 1356 BS PIB - high dose
Drug: BI 1356 BS tablet - high dose
Drug: BI 1356 BS tablet - low dose
Drug: BI 1356 BS tablet - high dose with food

First Posted Date: 2014-07-02

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02180503

Ketoprofen Lysine Salt as Mouthwash in Acute Phlogosis of the Pharyngeal Cavity Versus Benzidamine Hydrochloride

Phase 4

Completed

Conditions: Pharyngitis

Interventions: Drug: Benzidamine hydrochloride
Drug: Ketoprofen lysine salt

First Posted Date: 2014-06-30

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 214

Registration Number: NCT02178293

Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan low dose
Drug: Telmisartan high dose
Drug: Placebo

First Posted Date: 2014-06-30

Last Posted Date: 2014-06-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 82

Registration Number: NCT02178306

Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan, low dose
Drug: Telmisartan, high dose
Drug: Placebo

First Posted Date: 2014-06-27

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 26

Registration Number: NCT02176499

Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan + hydrochlorothiazide
Drug: Telmisartan
Drug: Placebo

First Posted Date: 2014-06-27

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 327

Registration Number: NCT02177500

Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan/hydrochlorothiazide

First Posted Date: 2014-06-27

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 100

Registration Number: NCT02177487

Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Device: Amlodipine
Drug: Telmisartan
Drug: Placebo

First Posted Date: 2014-06-27

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 431

Registration Number: NCT02177409

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy